Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis

Keiichiro Mori, Takafumi Yanagisawa, Wataru Fukuokaya, Kosuke Iwatani, Akihiro Matsukawa, Satoshi Katayama, Benjamin Pradere, Ekaterina Laukhtina, Pawel Rajwa, Marco Moschini, Simone Albisinni, Wojciech Krajewski, Alessia Cimadamore, Francesco Del Giudice, Jeremy Teoh, Fumihiko Urabe, Shoji Kimura, Masaya Murakami, Shunsuke Tsuzuki, Jun MikiKenta Miki, Shahrokh F. Shariat, Takahiro Kimura

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

Adjuvant immune checkpoint inhibitor therapies have radically altered the treatment landscape for renal cell carcinoma and urothelial carcinoma. However, studies have reported negative data regarding adjuvant immune checkpoint inhibitor therapies. Thus, this study aimed to assess the role of adjuvant immune checkpoint inhibitor therapy for both renal cell carcinoma and urothelial carcinoma. A systematic review and network meta-analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Multiple databases were searched for articles published as of February 2023. Studies were deemed eligible if they evaluated disease-free survival in patients with renal cell carcinoma and urothelial carcinoma receiving adjuvant immune checkpoint inhibitor therapy. Five studies met the inclusion criteria. In a network meta-analysis, pembrolizumab was shown to be the most effective regimen for patients with renal cell carcinoma, whereas nivolumab was found to be the most effective regimen for patients with urothelial carcinoma. Additionally, these results were consistently observed in a sub-analysis of the T stage. The present analysis provides findings that support the usefulness of adjuvant nivolumab therapy in urothelial carcinoma and adjuvant pembrolizumab therapy in renal cell carcinoma, in agreement with the currently available guidelines. However, the caveat is that the randomized controlled trials included in this analysis differed in important respects despite being similar in study design. Therefore, with these differences in mind, care needs to be taken when selecting patients for these immune checkpoint inhibitor therapies to maximize their benefits.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalInternational Journal of Urology
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 2024

Keywords

  • adjuvant immunotherapy
  • renal cell carcinoma
  • urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis'. Together they form a unique fingerprint.

Cite this